Additionally, the NMDA receptor being one of the key receptor target for KYNA, bifunctional KYNA-cannabinoid/σ1R ligands or co-administration of KYNA and cannabinoids might be a further therapeutic tool to utilize the CB1-NMDA receptor association in migraine or other neurological disorders. Here, CNR1 is linked to migraine disorder.